Last updated: February 27, 2026
What is the scope and core claims of Patent JP6265964?
Patent JP6265964 covers a pharmaceutical composition aimed at treating or preventing diseases associated with protein aggregation, such as neurodegenerative disorders. The patent claims focus predominantly on compounds, compositions, and methods related to inhibiting or reducing protein aggregation.
Key Claim Categories
- Chemical Compounds: The patent claims specific class of compounds, emphasizing small molecules with particular structural features conducive to inhibiting protein aggregation.
- Pharmaceutical Formulations: Claims extend to pharmaceutical compositions containing these compounds, optionally combined with carriers or excipients.
- Methods of Use: The patent includes claims covering methods for preventing or treating diseases like Alzheimer's disease, Parkinson's, and other neurodegenerative conditions by administering these compounds.
Notable Claims
- Claim 1: A compound with a specific chemical structure described by the patent's formula, which exhibits activity in inhibiting amyloid or alpha-synuclein aggregation.
- Claim 2: Pharmaceutical compositions containing at least one compound as described in Claim 1, combined with pharmaceutically acceptable carriers.
- Claim 3: Method of inhibiting protein aggregation in a subject by administering an effective amount of the claimed compound.
- Claim 4: Use of the compound for manufacturing a medicament for treating neurodegenerative diseases characterized by abnormal protein aggregation.
Claim Limitations
The scope is constrained to compounds meeting the structural criteria outlined, with supplementary considerations for dosage, administration route, and treatment timing. It emphasizes the activity against specific pathological proteins, limiting broader claims beyond the described chemical structures and applications.
How does the patent landscape look for related technology?
Patent Family and Priority
- The priority date is May 27, 2019, with filing dates in Japan.
- The patent family includes priority applications in China and the U.S. (US application number not specified in the initial data).
Related Patents
- Several related patents exist, focusing on small molecule inhibitors of amyloid or alpha-synuclein aggregation.
- Competitors such as Eisai, Biogen, and Novartis hold patents targeting similar mechanisms, particularly in amyloid beta and tau proteins.
Landscape Trends
- Recent filings (2019–2022) show a surge in patents centered on small molecules targeting neurodegeneration.
- A significant fraction of patents claims compounds with heteroaromatic frameworks, common in aggregation inhibitors.
- Patent filings increasingly cover combination therapies, integrating aggregation inhibitors with other symptomatic treatments.
Patentability and Freedom to Operate
- Patent JP6265964 has a well-defined chemical scope, but similar compounds are covered under other patents, raising potential freedom-to-operate challenges.
- Patent examiners actively evaluate novelty and inventive step based on prior art compounds with similar activity profiles.
Legal and Commercial Status
- The patent is granted in Japan and appears pending or granted in other jurisdictions based on priority filings.
- Commercialization exclusivity linked to this patent is expected through 2039 if maintained and enforced properly.
Market and competitive importance
- Patents like JP6265964 aim to secure exclusive rights for novel neurodegenerative disease treatments.
- The landscape indicates a highly competitive space with active patent applications, especially in small molecule inhibitors.
- The scope of JP6265964’s claims reflects attempts to delineate novel chemical entities with specific activity profiles.
Key Takeaways
- JP6265964 covers a class of chemical compounds aimed at inhibiting protein aggregation associated with neurodegenerative diseases.
- Its claims include specific compounds, formulations, and methods of use, limiting broad scope but providing strong protection within its chemical framework.
- It is part of a crowded patent landscape targeting small molecules for neurodegenerative conditions, with substantial activity by major pharma.
- Effective commercialization depends on navigating overlapping patents, especially those covering similar compound classes.
FAQs
1. Can I develop a drug using compounds outside the scope of JP6265964?
Yes. The patent claims specific chemical structures. Compounds outside these structures or with different mechanisms may avoid infringement.
2. How long is the patent protection for JP6265964?
Typically, Japanese patents expire 20 years from the filing date, which in this case is May 27, 2019. Patent expiry is expected around May 27, 2039.
3. Are there any infringement risks associated with similar compounds?
Potentially, especially with patents covering similar heteroaromatic compounds or aggregation inhibitors. A freedom-to-operate analysis is advised.
4. What are the competitive advantages of this patent?
The patent claims specific compounds with demonstrated activity against disease-associated protein aggregation, offering a legal barrier to competitors.
5. Is the patent enforceable outside Japan?
Enforceability depends on corresponding patents in other jurisdictions. The patent family includes filings in China and the U.S., offering broader territorial protection if granted.
References
- Patent JP6265964. (2023). [Details obtained from Japan Patent Office].
- WIPO. (2022). Patent Landscape Report on Neurodegeneration. [Online].
- U.S. Patent Application, Priority Filing May 27, 2019.
- European Patent Office. (2021). Patent filing data on small molecule aggregation inhibitors.
- World Patent Index. (2022). Analysis of patent activity in neurodegenerative drug space.
